IPillar
Life Science
Science Meets Strategy
Clinical-stage biotech and medtech with defensible IP, regulatory pathways already validated, and operators who have done it before.
ParadeplatzZürich · Switzerland
Strategic Capital.Shared Vision.
Moeller & Co. is a specialized investment boutique connecting professional capital with high-potential opportunities.
We don’t just invest; we invest together.
Three PillarsSingle MandateFinSA · SwitzerlandKreuzplatz 2 · 8032
01The Co. Philosophy
We do not invest alone. Every mandate is supported by a brain trust of founders with documented exits, former CEOs of listed corporations, top-tier consultants, and renowned industry experts.
The differentiator is not access to capital. It is access to judgment — the ability to evaluate roughly 400 opportunities a year and back fewer than 10 with conviction.
400
Reviewed / yr
10
Backed / yr
3
Pillars
02Three Pillars
A focused mandate, executed with discipline.
IIPillar
German Real Estate
Stability in Europe's Engine
Undervalued residential and commercial assets in Munich, Hamburg, Berlin and the Rhine corridor. Long hold periods. Patient capital.
IIIPillar
Disruptive Technologies
Backing the Builders
B2B SaaS, applied AI, and green-tech with revenue traction, defensible architecture, and founder–market fit.
03Current Focus · Pillar I
Moroxite AB
Orthobiology · Lund, Sweden · Clinical-Stage
A synthetic bone replacement for spinal fusion — eliminating the need for autologous bone harvest. Led by the founding team behind Bonesupport, the listed orthobiology company acquired in a multi-billion exit.
FDA Breakthrough Device Designation
$10B+
Annual market
1M+
Surgeries / yr
Q1 2028
First-in-human
$500M
Comparable exit
Comparable: CG Bio (Korea) — Novosis acquired by Nippon Zuki at early development for ~USD 500M.
04The Network
The value is the access.
Not the roster.
Founders with documented exits. Former CEOs of listed corporations. Top-tier consultants. Industry experts across our pillars. Names are introduced privately, when relevant to the conversation.
05Invitation to Connect
We evaluate roughly 400 opportunities a year.
We invest in fewer than 10.
For introductions, co-investment enquiries, or briefing access — please write directly.